SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (728)10/5/2005 1:46:59 PM
From: quidditch  Respond to of 1169
 
Boger, yup, what you said. And as to 950, it is, but as yet the numbers are so very small, which makes the program (and VRTX stock) replete with risk. Kind of where the rubber meets the road in BT. On the MAP kinase, as noted by others, there have been many failures along that road, and I don't have enough info to differentiate 702 m.o.a. It is orally delivered, and I'm not sure I've seen that before in a P38 MAP kinase inhibitor.

quid



To: rkrw who wrote (728)10/5/2005 10:54:25 PM
From: Miljenko Zuanic  Respond to of 1169
 
<<This was a typical case in point of what I was talking about. MMPD, something Boger had latched onto as a core piece of their hcv franchise, is now being scrapped. Which was very easy to predict. >>

If 950 is not what it is (whatever it is or will be???), Merimepodib will be alive for another 5-10 years, for sure.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News